KARYOPHARM THERAPEUTICS INC.
Selective Inhibitors of Nuclear Export (SINE) small molecules for autoimmune disease, specifically KPT-350 targeting auto-reactive plasma cells in systemic lupus erythematosus
New patent ·
Follows are private to you and power your alerts
Updated · karyopharmtherapeutics.com
- Sector
- Biotech
- Headquarters
- NEWTON, MA
- Founded
- 2008
- Latest Form D
- $165M, Dec 2022
- Total capital
- $210M
- Federal grants
- $4.4M
- 5 awards · 2016–2019
- Rank in peer group#501 of 514
- Private capital raised
- $205M
- 4 Form D · last Dec 2022
- 47 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 28
- 12 pending · first 2019
- Rank in peer group#4 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$165M
- Federal grantHealth and Human S · Phase II · Evaluating the impact of novel inhibitors of nuclear pore export in SLE$982K
- Federal grantHealth and Human S · Phase II · Evaluating the impact of novel inhibitors of nuclear pore export in SLE$2M
- Federal grantHealth and Human S · Phase II · Evaluating the impact of novel inhibitors of nuclear pore export in SLE$993K
- Federal grantHealth and Human S · Phase I · Evaluating the impact of novel inhibitors of nuclear pore export in SLE$225K
- Federal grantHealth and Human S · Phase I · Evaluating the impact of novel inhibitors of nuclear pore export in SLE$225K
- Private capital raisedForm D · SEC · 3rd filing$19M
- Private capital raisedForm D · SEC · 2nd filing$20.5M
- Private capital raisedForm D · SEC · 1st filing$700K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#4 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan BarberExecutive OfficerNamed in SEC Form D filings
- Barry E. GreeneDirectorNamed in SEC Form D filings
- Chen R. SchorDirectorNamed in SEC Form D filings
- Christy J. OligerDirectorNamed in SEC Form D filings
- Deepika E. PakianathanDirectorNamed in SEC Form D filings
- Garen G. BohlinDirectorNamed in SEC Form D filings
Show all 20 people
- Kenneth E. WegDirectorNamed in SEC Form D filings
- Mansoor Raza MirzaDirectorNamed in SEC Form D filings
- Michael KauffmanExecutive Officer, DirectorNamed in SEC Form D filings
- Michael ManoExecutive OfficerNamed in SEC Form D filings
- Michael MasonExecutive OfficerNamed in SEC Form D filings
- Paul BrannellyExecutive OfficerNamed in SEC Form D filings
- Peter G. HonigDirectorNamed in SEC Form D filings
- Reshma RangwalaExecutive OfficerNamed in SEC Form D filings
- Richard PaulsonExecutive Officer, DirectorNamed in SEC Form D filings
- Ronald DePinhoDirectorNamed in SEC Form D filings
- Sharon E. ShachamExecutive OfficerNamed in SEC Form D filings
- Sohanya ChengExecutive OfficerNamed in SEC Form D filings
- Stephen MitchenerExecutive OfficerNamed in SEC Form D filings
- Stuart PoultonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 28 granted of 40- New patentUses Of IL-12 As A Replacement ImmunotherapeuticUSPTOUS 12,766,188
- PendingCo-crystal Forms Of SelinexorUSPTOApplication 19534167
- GrantedCrystalline Form Of SelinexorUSPTOUS 12,709,609
Show all 40 patent records
- Uses Of IL-12 As A Replacement ImmunotherapeuticOct 20, 2026 · US 12,766,188Granted
- Co-crystal Forms Of SelinexorSep 3, 2026 · Application 19534167Pending
- Crystalline Form Of SelinexorAug 18, 2026 · US 12,709,609Granted
- Methods Of Synthesis Of Heteroaryl Derivatives Of Triazolyl Acrylamides And Crystalline FormsJul 7, 2026 · US 12,673,939Granted
- Polymorphs Of SelinexorJun 4, 2026 · Application 19258063Pending
- Substituted Benzofuranyl And Benzoxazolyl Compounds And Uses ThereofMar 26, 2026 · Application 19197345Pending
- Nuclear Transport Modulators And Uses ThereofMar 17, 2026 · US 12,577,225Granted
- Hydrazide Containing Nuclear Transport Modulators And Uses ThereofMar 5, 2026 · Application 19075233Pending
- Co-crystal Forms Of SelinexorFeb 24, 2026 · US 12,559,478Granted
- Process For Preparing XPO1 Inhibitors And Intermediates For Use In The Preparation Of XPO1 InhibitorsNov 25, 2025 · US 12,479,806Granted
- Polymorphs Of SelinexorJul 29, 2025 · US 12,371,420Granted
- Substituted Benzofuranyl And Benzoxazolyl Compounds And Uses ThereofJun 17, 2025 · US 12,331,040Granted
- The Combination Of XPO1 Inhibitors And Second Agents For The Treatment Of Prostate CancerJun 3, 2025 · US 12,318,386Granted
- Hydrazide Containing Nuclear Transport Modulators And Uses ThereofMay 6, 2025 · US 12,291,508Granted
- Nuclear Transport Modulators And Uses ThereofNov 14, 2024 · Application 18526900Pending
- Uses Of IL-12 As A Replacement ImmunotherapeuticJun 6, 2024 · Application 16318670Pending
- Nuclear Transport Modulators And Uses ThereofApr 2, 2024 · US 11,945,794Granted
- Crystalline Form Of SelinexorDec 7, 2023 · Application 18032949Pending
- Polymorphs Of SelinexorNov 7, 2023 · US 11,807,629Granted
- Hydrazide Containing Nuclear Transport Modulators And Uses ThereofOct 17, 2023 · US 11,787,771Granted
- Polymorphs Of SelinexorSep 12, 2023 · US 11,753,401Granted
- Polymorphs Of SelinexorSep 5, 2023 · US 11,746,102Granted
- Biomarkers For SelinexorJun 9, 2022 · Application 17598101Pending
- IL-12 Compositions And Methods Of Use In Hematopoietic RecoveryJun 2, 2022 · Application 17368346Pending
- Nuclear Transport Modulators And Uses ThereofFeb 24, 2022 · Application 17307656Pending
- Nuclear Transport Modulators And Uses ThereofSep 21, 2021 · US 11,124,493Granted
- Polymorphs Of SelinexorAug 3, 2021 · US 11,078,190Granted
- Hydrazide Containing Nuclear Transport Modulators And Uses ThereofJun 15, 2021 · US 11,034,660Granted
- Substituted Benzofuranyl And Benzoxazolyl Compounds And Uses ThereofMay 18, 2021 · US 11,008,309Granted
- Multicyclic Compounds And Uses ThereofDec 8, 2020 · US 10,858,347Granted
- Nuclear Transport Modulators And Uses ThereofJul 14, 2020 · US 10,709,706Granted
- Nuclear Transport Modulators And Uses ThereofMar 19, 2020 · Application 16394986Pending
- Hydrazide Containing Nuclear Transport Modulators And Uses ThereofJan 28, 2020 · US 10,544,108Granted
- Nuclear Transport Modulators And Uses ThereofJan 7, 2020 · US 10,526,295Granted
- Polymorphs Of SelinexorDec 31, 2019 · US 10,519,139Granted
- Nuclear Transport Modulators And Uses ThereofSep 10, 2019 · US 10,407,405Granted
- Substituted Benzofuranyl And Benzoxazolyl Compounds And Uses ThereofSep 3, 2019 · US 10,399,963Granted
- (S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3-METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4-FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE For The Treatment Of CancerJul 30, 2019 · US 10,363,247Granted
- 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT ModulatorsJul 18, 2019 · Application 15752542Pending
- Methods of Promoting Wound Healing Using CRM1 InhibitorsFeb 12, 2019 · US 10,202,366Granted
Related companies, and why
- OverT Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Gila Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SANARENTERO LLCSimilar federal contract value in Biotech · null in contracts
- Umoja BiopharmaSimilar federal contract value in Biotech · null in contracts
- ADARx PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- COARE HOLDINGS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .